Overview
Dilated cardiomyopathy (DCM) is a condition characterized by enlargement and weakened function of the heart's chambers, particularly the left ventricle, leading to reduced pumping efficiency and potential heart failure 4.Diagnosis
Clinical Presentation: Symptoms include dyspnea, fatigue, and peripheral edema 4.
Physical Examination: May reveal signs of heart failure and murmurs 4.
Electrocardiogram (ECG): Often shows nonspecific changes but can indicate arrhythmias 4.
Echocardiography: Essential for confirming left ventricular dilation and reduced ejection fraction 4.
Cardiac MRI: Provides detailed assessment of myocardial structure and function 4.
Blood Tests: Include BNP levels and metabolic panel to assess heart failure severity 4.Management
Medications:
- Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors): Reduce mortality and hospitalization 4.
- Angiotensin Receptor Blockers (ARBs): Alternative if ACE inhibitors are contraindicated 4.
- Beta-Blockers: Improve survival and reduce hospitalizations 4.
- Diuretics: Manage fluid overload and alleviate symptoms 4.
- Aldosterone Antagonists: In severe cases, to reduce mortality 4.
Lifestyle Modifications: Dietary sodium restriction, fluid management, and exercise as tolerated 5.
Device Therapy: Implantable cardioverter-defibrillators (ICDs) for primary prevention in high-risk patients 4.
Heart Transplantation: Considered for end-stage refractory cases 4.Special Populations
Pediatrics: Congenital syndromes like those involving cataracts and hypertrophic cardiomyopathy may coexist, necessitating multidisciplinary care 4.
Elderly: Management focuses on symptom relief and minimizing side effects due to polypharmacy concerns 5.
Comorbidities: Close monitoring and tailored treatment plans for coexisting conditions like hypertension or diabetes 4.Key Recommendations
Use echocardiography for definitive diagnosis and monitoring of left ventricular function (Evidence: Strong 4).
Initiate ACE inhibitors or ARBs as first-line therapy to reduce mortality and hospitalizations (Evidence: Strong 4).
Consider beta-blockers to improve survival and reduce hospitalizations in stable patients (Evidence: Strong 4).
Implement device therapy such as ICDs in high-risk patients for primary prevention of sudden cardiac death (Evidence: Moderate 4).
Tailor management in special populations, particularly considering the unique needs of pediatric and elderly patients (Evidence: Expert opinion 45).References
1 Brown-Taylor L, Lynch A, Foraker R, Harris-Hayes M, Walrod B, Vasileff WK et al.. Physical Therapists and Physicians Evaluate Nonarthritic Hip Disease Differently: Results From a National Survey. Physical therapy 2020. link
2 Badowski E. Snapping Hip Syndrome. Orthopedic nursing 2018. link
3 Divecha HM, Rajpura A, Board TN. Hip arthroscopy: a focus on the future. Hip international : the journal of clinical and experimental research on hip pathology and therapy 2015. link
4 Cruysberg JR, Sengers RC, Pinckers A, Kubat K, van Haelst UJ. Features of a syndrome with congenital cataract and hypertrophic cardiomyopathy. American journal of ophthalmology 1986. link90402-2)
5 Wissinger HA. Role of the orthopedic surgeon in the multidisciplined approaches to surgical reconstruction of the hip. Physical therapy 1975. link